Clinical Trials Logo

Clinical Trial Summary

The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo. The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion by examining differential effects on hematoma and edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03954041
Study type Interventional
Source Remedy Pharmaceuticals, Inc.
Contact
Status Terminated
Phase Phase 2
Start date October 6, 2019
Completion date June 27, 2023

See also
  Status Clinical Trial Phase
Completed NCT02858544 - Concussion in Motor Vehicle Accidents: The Concussion Identification Index N/A